Chemical Information | |
Antiviral agent ID | DrugRepV_4814 | |
Antiviral agent name | 3-[(4Z)-3-methyl-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid | |
IUPAC Name | 3-[(4Z)-3-methyl-5-oxo-4-[(5-phenylfuran-2-yl)methylidene]-4,5-dihydro-1H-pyrazol-1-yl]benzoic acid | |
SMILES (canonical) | [H]C1=CC=C([H])C(=C1)C1=CC=C(O1)\C=C1\C(C)=NN(C1=O)C1=CC=CC(=C1)C(O)=O | |
Molecular Formula | C22H16N2O4 | |
Molecular Weight (g/mol) | 372.38 | |
InChl | InChI=1S/C22H16N2O4/c1-14-19(13-18-10-11-20(28-18)15-6-3-2-4-7-15)21(25)24(23-14)17-9-5-8-16(12-17)22(26)27/h2-13H,1H3,(H,26,27)/b19-13- | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Middle East respiratory syndrome coronavirus (MERS-CoV) NA NA | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Drug concentration) | >50 μM
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Type of Inhibition) | IC50 [ 50 % ] | |
Reference | Kumar V, Tan KP, Wang YM, Lin SW, Liang PH..Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors..Bioorg Med Chem. 2016 Jul 1;24(13):3035-3042. doi: 10.1016/j.bmc.2016.05.013. Epub 2016 May 12. PMID:27240464
| |
Comment | Docking studies show that a carboxylate present at either R1 or R4 destabilizes the oxyanion hole in the 3CLpro. Compounds 3f, 3g and 3m could inhibit both NA and 3CLpro and serve as a starting point to develop broad-spectrum antiviral agents.
| |